See J.H. Reichman, “The International Legal Status of Undisclosed Clinical Trial Data: From Private to Public Good?” [ However, in order for a competitor to be able to market a generic copy of the drug, the local DRA must still make a judgment about the efficacy and safety of the generic product, and this decision may require the authority to rely on the regulatory decisions made by a DRA in a country where the originator has actually been granted regulatory approval. Again, the originator company may argue that the generic producer free rides on the originator’s efforts, even though the domestic DRA in these cases makes no direct use of the test data in question (rather, it uses the foreign decision that is based on such test data).